Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
──────────
**Beta Finch Podcast Script: IBM Q2 2026 Earnings**

---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into IBM's second quarter 2026 results.

JORDAN: And Alex, this is a juicy one — there was already a pre-announcement before the official call, so expectations were... managed, let's say.

ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Solid. Okay, let's talk numbers. Revenue growth of just 1% for the quarter — that's a real miss for IBM, which has been on a growth acceleration story for a while now.

ALEX: Right, and CEO Arvind Krishna didn't sugarcoat it — he said flat out the quarter "fell short of expectations." But here's the twist: it wasn't a demand problem across the board, it was concentrated.

JORDAN: Exactly. CFO Jim Kavanaugh explained that in the final weeks of June, clients suddenly redirected spending toward servers, storage, and memory — basically rushing to lock in infrastructure ahead of expected price increases. That caused tens of large enterprise license deals to slip.

ALEX: And when those deals slip, it hits IBM's mainframe-and-software bundle hard. Transaction processing software revenue was down 9% for the quarter, and if you isolate the mainframe hardware itself, it was down 42% year over year.

JORDAN: Which sounds alarming, but context matters — that's coming off 70% growth in the same quarter last year during the z17 launch. And even with the dip, the z17 cycle is still running at nearly 130% program-to-program versus the z16 cycle, which was IBM's best ever.

ALEX: So it's more "lumpy" than "broken."

JORDAN: That's the bet management is making. And here's a number I liked — about 80% of IBM's software revenue is recurring, subscription or consumption-based, and that grew nicely, accelerating from 7% to 8% year over year. The real damage was isolated to that other 20%, the transactional, CapEx-sensitive chunk.

ALEX: Free cash flow was a bright spot too — $4.8 billion through the first half, flat year-over-year, and management reaffirmed guidance to grow full-year free cash flow by about $1 billion.

JORDAN: Which is honestly the more impressive headline given the revenue miss. Kavanaugh pointed to strong underlying EBITDA growth, plus they front-loaded a lot of the cash tax and CapEx headwinds earlier in the year, so those pressures ease up in the second half.

ALEX: Let's talk guidance — full-year revenue growth is now expected at 4% to 5%, down from the prior 5%-plus target. Software guidance moved to 6% to 8% for the year.

JORDAN: And this is the part analysts kept pushing on during Q&A — is this demand deferred, or demand destroyed? Arvind's answer was pretty specific: of the roughly ten large deals that slipped, about a third had already closed in just the first three weeks of the new quarter. He called that "a good indication, not yet full evidence" that clients are delaying, not canceling.

ALEX: He also had a great explanation for why it happened — clients apparently didn't realize alternate infrastructure purchases were jumping 30% in price quarter to quarter until crunch time, so they diverted budget there and pushed off other spending, including IBM software bundled with hardware purchases.

JORDAN: On the strategic side, there's a lot going on beyond the mainframe story. Distributed infrastructure — think Power and storage — had its best quarter of revenue growth on record, up 37%, with $500 million in backlog, the highest ever.

ALEX: And IBM's leaning hard into AI positioning — watsonx Orchestrate, Red Hat, the Confluent and HashiCorp acquisitions, all framed around this idea of being

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown of the biggest names in the market. Here's the script for PMI's Q2 2026 call.

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Philip Morris International's second quarter 2026 results — and there's a lot going on here, including a CFO transition. But first, the standard stuff: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Right, and PMI gave us plenty to unpack. Let's start with the headline numbers, because they were strong.

**ALEX:** Very strong. Organic net revenue growth of +8% for the quarter, operating income up +11%, and adjusted diluted EPS hit $2.20 — that's +14% currency-neutral, +15% in dollar terms. Quarterly net revenue crossed $11 billion for the first time ever.

**JORDAN:** And this wasn't just a currency tailwind story either. Outgoing CFO Emmanuel Babeau flagged that about a third of the EPS beat came from a favorable tax-related currency effect tied to the Russian ruble, but two-thirds was real operating strength — better SG&A phasing and a surprisingly strong combustible business.

**ALEX:** Let's talk about that smoke-free business first, because it's really the engine of this whole story. IQOS adjusted in-market sales volume grew +5% in the quarter — that sounds almost modest until you realize it includes two known headwinds: an excise tax hike in Japan and a flavor ban in Poland.

**JORDAN:** Strip those out and IQOS growth was over 10% in Q2, north of 11% for the first half. That's the real underlying trend. IQOS also just cracked Kantar's list of top 100 most valuable global brands — pretty remarkable for a product that's only a decade old.

**ALEX:** VEEV, their vapor brand, had an absolutely wild quarter — shipments up 55% in Q2, 72% for the half. Management says it's now the number one closed-pod brand in Europe and in global travel retail.

**JORDAN:** Now let's get into the U.S., because this is where investors have been the most impatient. ZYN shipments grew 2% year-over-year to 2.9 billion pouches, and importantly, that's despite lapping an inventory tailwind from last year. Sequentially versus a rough Q1, U.S. net revenue was up 38%, gross profit up 46%.

**ALEX:** The bigger story is the product lineup. They just launched ZYN Ultra — a lower-priced moist variant meant to close the gap with competitors — and they're bringing 1.5 and 8 milligram dry formats in Q3. Babeau was pretty clear-eyed that it's early days, just two weeks of data on Ultra, but the initial read and consumer feedback were encouraging.

**JORDAN:** And there's a regulatory tailwind too — ZYN got Modified Risk Tobacco Product authorization on 20 SKUs, the only nicotine pouch product with that designation. That lets them actually market reduced-risk claims versus cigarettes, which is a real differentiator.

**ALEX:** Here's the strategic pivot that stood out to me: management is choosing to step up U.S. investment hard in the second half — more marketing, a new brand campaign called "When It Clicks," expanded distribution — partly to build ZYN and partly to lay the groundwork for IQOS ILUMA's eventual U.S. launch, pending FDA action.

**JORDAN:** Which is why, despite beating estimates two quarters in a row, PMI held its full-year guidance rather than raising it. An analyst from Goldman actually pushed on this directly, and Babeau basically confirmed: yes, the flat guidance reflects the decision to plow incremental profit back into U.S. investment rather than let it drop straight to the bottom line.

**ALEX:** Let's touch on combustibles too, because cigarettes had a surprisingly strong quart

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex.

JORDAN: And I'm Jordan. Before we dive in, quick disclaimer:

ALEX: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: With that out of the way — Alex, today we're on GE Vernova, ticker GEV, Q2 2026. And this is one of those quarters where I read the numbers twice because they seemed almost too good.

ALEX: Right, let's just start with the headline: orders came in at $24.2 billion for the quarter, up 88% year-over-year. That's a book-to-bill ratio of over 2x, meaning they're booking twice as much business as they're actually shipping and billing right now.

JORDAN: Which tells you the backlog is just ballooning. And it did — total backlog hit $176 billion, up $13 billion sequentially. CEO Scott Strazik said they're on track for $200 billion by 2027.

ALEX: The engine behind all this is really Gas Power. They signed 20 gigawatts of new orders and slot reservations this quarter alone, pushing their total gigawatts under contract from 100 to 116. And they're now saying they expect to hit at least 125 gigawatts by year-end.

JORDAN: What stood out to me is the mix — more than half of that contracted capacity is for their big HA turbines, the ones expected to run baseload for decades. That's not speculative demand, that's utilities and data centers locking in power for the long haul. And notably, about 80% of that demand is still traditional customers, only 20% data centers — so despite all the AI hype, this isn't just a data center story.

ALEX: Though the data center piece is growing fast too. Electrification booked $2.7 billion in data center orders this quarter, bringing the first-half total north of $5 billion — more than double all of 2025.

JORDAN: Let's talk margins, because that's really the story underneath the story. Adjusted EBITDA grew 61% year-over-year to $1.2 billion, and margin expanded 340 basis points. First-half margins are up 360 basis points versus last year, even as lower-margin-mix equipment revenue grows faster than services.

ALEX: And free cash flow — this is the number that jumped out at me — $5.1 billion generated in the quarter alone. Year to date they're at roughly $10 billion, which is already two and a half times what they did in all of 2025.

JORDAN: A lot of that is working capital benefit from customer down payments on all those gas turbine slot reservations. It's real cash, but investors should understand some of that first-half strength is front-loaded — CFO Ken Parks was upfront that second-half free cash flow will be notably lower than the first half.

ALEX: Which is why the full-year guidance raise is still notable in context. Revenue guidance moved up to $45.5 to $46.5 billion, and free cash flow guidance jumped from $6.5-$7.5 billion to $11.5-$12.5 billion.

JORDAN: That's almost double the original free cash flow guide. EBITDA margin guidance held steady at 12-14% for the year.

ALEX: Let's hit segment performance quickly. Power segment orders more than doubled, revenue up 14%, EBITDA margin expanded 320 basis points to 18.8%. Electrification was even more dramatic — orders up 66% to $6.3 billion, revenue up 68% on a reported basis, margin up 700 basis points to 18.4%.

JORDAN: Wind is the laggard, as expected. Orders down 40%, mostly onshore weakness in North America tied to permitting delays and tariff uncertainty. EBITDA losses of $275 million this quarter, and they're still guiding to roughly $400 million in losses for the full year. Management's basically saying: we're managing what we can control there and waiting for pol

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
**BETA FINCH — CME GROUP Q2 2026 EARNINGS BREAKDOWN**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into CME Group's second quarter 2026 results — and trust me, there is a LOT to unpack here beyond just the numbers.

JORDAN: Yeah, this one's spicy. We've got record revenue, but the real story is CME going toe-to-toe with the entire perpetual futures narrative that's been dominating headlines.

ALEX: Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Solid. Okay, let's start with the numbers, because they're genuinely strong.

ALEX: Right. Revenue came in at just over $1.7 billion, up 1% year-over-year — that's a record for a second quarter and the second-highest quarterly revenue in company history, only behind Q1 of this year. Average daily volume was 29.8 million contracts, the second-best Q2 ever, within 1% of last year's record.

JORDAN: And the real headline for me is market data — $238 million in revenue, up 20% year-over-year. That's 33 consecutive quarters of year-over-year growth. Thirty-three! That's not a hot streak, that's a business model.

ALEX: It's wild. And adjusted EPS came in at $2.99, up 1% from last year, with a 69.5% adjusted operating margin. For a company this size, that margin is just remarkable.

JORDAN: They also returned $1.2 billion to shareholders in the quarter — $468 million in dividends, $695 million in buybacks. And CFO Lynne McGregor, who's stepping into a bigger strategic role, noted July is already tracking 18% ahead of last year. So momentum's not slowing down.

ALEX: Okay, now let's get into the thing everyone on the call wanted to talk about — perpetual futures. Multiple analysts pressed CEO Terry Duffy on this, and he came out swinging.

JORDAN: He really did. His argument, basically boiled down: perpetuals are functionally leveraged spot products dressed up as futures. No expiration date, funding rate resets, auto-liquidation mechanics — and he says none of that works for the institutional risk managers who make up 94% of CME's volume.

ALEX: He had this great anecdote about calling the CEO of a major energy trading firm and asking — I think he said nineteen times — whether they wanted CME to list a perpetual oil contract. Answer: no, every time. They said they couldn't risk-manage their book with something that just tracks leveraged spot price.

JORDAN: And on the crypto comparison — which is really the only apples-to-apples perpetuals data point that exists right now — CME's Tim McCourt laid out some pretty stark numbers. CME's doing $4.5 to $6.5 billion a day in crypto derivatives volume, versus about $270 million a day for a Bitcoin perpetual that a competitor, Kalshi, launched in July. Open interest gap was even bigger — $9-10 billion at CME versus $10 million for that perpetual product.

ALEX: So the message is basically: "We could launch these tomorrow if there were real demand, but the demand just isn't showing up where it matters."

JORDAN: Right, and Duffy was pretty direct that this isn't a defensive posture — CME says it has contract specs ready to go. It's a "we'll do it when it makes sense" stance, not a "we can't compete" stance.

ALEX: Let's talk product pipeline, because there's a lot coming. Twenty-four-seven crypto futures trading launched this quarter. This weekend, round-the-clock gold trading goes live. Next week, Single Stock futures relaunch — this is CME's second attempt at that product after a failed joint venture back in 2000.

JORDAN: Duffy's reasoning on timing there was interesting — he basically said the market has evolved, equity valuations are much higher now, and in

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the numbers and the narrative behind the headlines. I'm Alex.

JORDAN: And I'm Jordan. Today we're digging into Chubb Limited's Q2 2026 results.

ALEX: Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good disclaimer to lead with, especially for a name like Chubb where there's a lot of moving parts. Let's set the scene.

ALEX: Big quarter for the property and casualty giant. Core operating earnings came in at $2.8 billion, or $7.26 per share — that's up 14.6% on the earnings side and 18.2% on EPS year-over-year.

JORDAN: And tangible book value per share, which CEO Evan Greenberg calls their most important measure of shareholder wealth creation, was up 17.1% year-over-year. That's a real headline number for an insurer.

ALEX: Underwriting was the star. P&C underwriting income was over $1.9 billion, up almost 19%, with a combined ratio of 83.8%. Strip out catastrophes and look at the current accident year, and it's 82.2%.

JORDAN: For listeners who don't live in insurance-speak, combined ratio under 100 means they're making underwriting profit before you even count investment income. Anything in the low 80s is genuinely excellent.

ALEX: Investment income was also a record — $1.88 billion, up more than 11%. Their invested asset base is now $175 billion, up from $161 billion a year ago. New money is going in at a 5.5% yield, well above their current 5.1% book yield.

JORDAN: That reinvestment spread is a nice tailwind — every maturing bond gets replaced with something yielding more, so investment income keeps compounding almost on autopilot.

ALEX: Now here's where it gets interesting. Growth wasn't uniform across the business, and Greenberg was pretty blunt about why.

JORDAN: Right, global P&C premiums were up 3% — but strip out large account and E&S property, which they're intentionally shrinking, and it's actually 6.3%. He specifically called out that pricing in casualty lines is starting to lag loss cost inflation, which he pegged at 6 to 7% for primary casualty and 9.5 to 12% for excess casualty.

ALEX: And he didn't hold back on competitors either — talked about newer players and MGAs writing business on terms that experienced underwriters walked away from decades ago.

JORDAN: That's classic late-cycle soft market behavior. He also flagged London wholesale actively writing U.S. casualty again, which he said is "a movie we've seen before" — that's not a compliment.

ALEX: Meanwhile, the parts of the business firing on all cylinders: international retail grew almost 12%, Latin America 15.6%, Asia 12%. North America middle market and small commercial grew almost 9%. And their high net worth personal lines business — the one differentiated, non-commodity business — grew 6% with 90% retention.

JORDAN: That diversification story is really the thesis of the whole call. When a reporter pushed on why Chubb sounds so much more cautious than some peers, Greenberg's answer was essentially: I can't speak for anyone else, I call it as I see it, and the results speak for themselves.

ALEX: There was also a fun exchange about reinsurance — an analyst asked if Chubb might buy a reinsurer to build scale there, and Greenberg's answer was just, quote, "it makes zero sense." Pretty definitive.

JORDAN: Short and blunt — that's very on-brand for him this call. Another notable moment: someone asked about rising AI and token costs eating into the tech efficiency gains insurers have been promising. Greenberg said Chubb tracks its token costs in hard dollars and called them "a fraction, a minor fraction" relative to the efficien

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026 results. Before we get going, I do need to say — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And with that out of the way, Alex, this was actually a pretty strong quarter for Intuitive on paper.

ALEX: It was. Revenue up 19% to $2.89 billion, non-GAAP EPS up 28% to $2.80 a share, operating margin at 42%. Total procedures grew 16%, with da Vinci procedures up 15% and Ion — their lung biopsy platform — up a huge 36%.

JORDAN: There's a wrinkle in that gross margin number though. It came in at 70%, but $36 million of that was a one-time tariff refund benefit. Strip that out and you're looking at 68.7%, which is still solid, but worth noting when you're comparing quarters.

ALEX: Right, and they actually raised full-year gross margin guidance because of that — now 68% to 69%, up from 67.5% to 68.5%. But here's the part that got analysts' attention: U.S. da Vinci procedure growth moderated to 12%, down from 14% in Q1.

JORDAN: Yeah, and CFO Jamie Samath was pretty direct about why. They're seeing signs that patients are deferring elective procedures, and they specifically flagged the expiration of ACA enhanced premium subsidies as a factor. Basically, when people's insurance costs go up or coverage gets murkier, they push off surgeries that can wait.

ALEX: The CEO, Dave Rosa, made a point of saying the underlying disease burden hasn't changed — people aren't getting healthier, they're just delaying care. Which, if you're an investor, is either reassuring or a "wait and see," depending on how you read it.

JORDAN: There's also the GLP-1 story continuing to play out — bariatric procedures in the U.S. declined high-single-digits this quarter as more patients manage weight through drugs like Ozempic instead of surgery.

ALEX: Let's talk strategy, because there was a lot packed into this call. The big one: the Extended Use Program. Starting in early 2027, Intuitive plans to increase the number of uses allowed on a subset of their EndoWrist instruments, specifically targeting lower-cost, high-volume benign procedures.

JORDAN: This is a classic Intuitive move — they did something similar back in 2020. The idea is: lower the cost per procedure for hospitals, which drives more adoption, which drives more scale. An analyst on the call, Travis Steed, tried to get them to size the financial impact — he was fishing for whether this repeats the roughly 7-point hit to instrument revenue per procedure they saw last time.

ALEX: And management wouldn't bite. Jamie Samath said flat out they're not ready to quantify it and will give more detail next quarter. So that's a real overhang to watch heading into 2027 guidance.

JORDAN: The other big theme was geographic. China remains genuinely tough — increased domestic robotic competition, pricing pressure, and a new centralized tender process the government is rolling out. Dave Rosa was careful to say it's not quite the same as the volume-based pricing programs we've seen hit other device makers, but it's clearly something to watch.

ALEX: Japan, on the other hand, looked more encouraging. New reimbursement policies kicked in June 1st, and they already saw system placements jump — 25 systems in Japan this quarter versus 15 a year ago.

JORDAN: And then there's da Vinci 5, which is really the growth engine right now. They placed 468 total da Vinci systems, 246 of those were da Vinci 5, including 114 dual-console setups. The installed base is over 1,700 systems and 15,000 surgeons trained on it already.

ALEX: One thing that stood out to me in t

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: BANKS (https://betafinch.com/groups/BANKS)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown of the numbers that matter, the stories behind them, and what it all means for you.

ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan, and today we're digging into Charles Schwab's Q2 2026 results — and Jordan, this one's got a headline number that jumped off the page.

JORDAN: It really did.

ALEX: Before we get into it, quick reminder — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Right, so let's start with the topline. Schwab posted $7.1 billion in total revenue, up 21% year-over-year, and adjusted EPS of $1.62 — that's a 42% jump from last year. That's not incremental growth, that's a genuinely strong quarter.

ALEX: And it wasn't just one line item carrying the load. Net interest revenue was up 19%, asset management fees up 16% to $1.8 billion, and trading revenue jumped 28% to $1.2 billion on 11.9 million daily average trades. That's a company firing on basically every cylinder.

JORDAN: What stood out to me is where that net interest strength is coming from. It's not just sitting on deposits and collecting spread passively — bank lending balances hit $67 billion, up 33% year-over-year, largely driven by their Pledged Asset Line product. Clients are borrowing against their portfolios instead of selling appreciated stock, which is a pretty clever way to deepen the relationship without pushing clients out of their positions.

ALEX: Yeah, CEO Rick Wurster made that point explicitly in the call — someone with a big embedded gain who wants access to cash, they don't want to sell and trigger taxes, so they pledge the assets instead. And apparently only about half a percent of Schwab clients use one of these lending products today, versus 4% industry-wide. So there's a long runway there.

JORDAN: That "lending penetration gap" language really jumped out at me. If they can even partially close that gap, it's a meaningful, durable growth lever — not a one-quarter sugar high.

ALEX: Let's talk client growth too, because the numbers there are big. 1.4 million new brokerage accounts in the quarter, $120 billion in core net new assets — up almost 50% year-over-year. And zooming out to the first half of the year, $2.7 million new accounts and $260 billion in net new assets.

JORDAN: And management reiterated they expect 5% or higher organic growth as the long-term target across their three businesses — Investor Services, Advisor Services, and the workplace/retirement business. Advisor Services in particular has been running above that, 6%-plus the last four quarters, as independent RIAs keep gaining share.

ALEX: There's also a strategic thread running through this call that I think is worth pulling on — Schwab really positioning itself as the "one-stop shop" for people's entire financial life. Wealth, banking, lending, trading, and now increasingly private markets and crypto.

JORDAN: Right, they closed the Forge acquisition for private markets access, they're piloting crypto transfers by the end of the month, and they made an investment in Paxos to support that crypto rollout. None of that is moving the needle financially yet — CFO Mike Verdeschi was upfront that these are smaller contributors for now — but it rounds out the platform.

ALEX: The wealth advice opportunity might actually be the bigger long-term story, though. Wurster pointed out the U.S. retail advice market is $37 trillion, and Schwab only has about 2% share. Only 5% of Schwab retail households are currently on a fee-based advice solution, even though 31% say they'd be willing to pay for advice.

JORDAN: And clients on their Schwab Wealth Advisory offer generate t

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME), INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into 3M's second quarter 2026 results, and there's a lot to unpack here. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And Alex, this was genuinely a strong quarter for 3M. Organic growth of 5.4%, operating margin at 24.9% — that's their highest ever, by the way — EPS of $2.40, up 11% year-over-year, and free cash flow of $1.3 billion with 107% conversion. That's about as clean a beat as you'll see.

ALEX: Right, and they didn't just beat expectations, they raised guidance across the board. Full-year organic growth guidance moved from 3% to greater than 3.5%. EPS guidance went from $8.50-$8.70 up to $8.80-$8.95. Free cash flow guidance ticked up $100 million to $4.7-$4.9 billion.

JORDAN: What stood out to me is CEO Bill Brown was pretty emphatic this isn't a macro tailwind story. CFO Anurag Maheshwari basically said the same thing on the call — this is internal execution. Commercial excellence initiatives, better sales force effectiveness, cross-selling that's running 40% ahead quarter-over-quarter, and customer attrition improving about 200 basis points, mostly in their Safety & Industrial business.

ALEX: And the innovation piece is a big part of the story too. They launched 92 new products in the quarter, up 44% year-over-year, putting them on pace for more than 350 new products this year. They're targeting over 1,000 new product launches by 2027, and development cycle time is down about 20%.

JORDAN: The segment breakdown really tells the story. Safety & Industrial — that's SIBG — grew 8.2%, with double-digit growth across electrical markets, adhesives and tapes, abrasives, and industrial specialties. Transportation and Electronics grew 5.9%, helped by strength in semiconductors, aerospace, and data centers. But Consumer was the soft spot, down 2.1% for the quarter because of some retailer destocking in late June.

ALEX: Now let's talk about the headline strategic news, because this is the part that got analysts excited. 3M announced a partnership with Microsoft — they're the first hyperscaler to deploy 3M's Expanded Beam Optical technology, or EBO, in Azure data centers.

JORDAN: This is fascinating from a materials science angle. EBO is basically a more durable, dust-resistant fiber optic connector that Brown said can cut installation time in data centers by about 85%. They've got 100 patents already, 50 more pending. Revenue this year is only in the $40-50 million range, but Brown said it could scale 4x or 5x — or more — over the next few years as the broader market shifts from copper to optical.

ALEX: And they're not trying to own the whole ecosystem either. They formed a 44-player multi-supplier agreement across hyperscalers, chip makers, and connector manufacturers. Brown was clear — they won't succeed as a sole provider, this is about industry-wide adoption.

JORDAN: There was also the Madison Fire & Rescue deal — they closed on July 1st, folding it into their Scott SCBA business as a majority-owned joint venture, and picked up $700 million in cash in the process. That JV does about $800 million in revenue, growing high single digits with above-average margins. Classic example of reshaping the portfolio toward higher-growth, higher-margin businesses.

ALEX: One thing I want to flag from the Q&A — China came up, and it's a much better story than a lot of people expected. Double-digit growth in the quarter, about 8% for the first half, and that's the seventh straight quarter of double-digit growth in India specifica

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: FAANG (https://betafinch.com/groups/FAANG)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Netflix's Q2 2026 numbers, and there's a lot to unpack here.

Before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Alright Alex, let's start with the topline. Revenue growth is guided at 12% for Q3, 11% FX-neutral, which is a slight deceleration from Q2's 12%. Some analysts flagged that.

ALEX: Right, but CFO Spencer Neumann pretty much waved that off. His point was they don't manage quarter to quarter — they manage to the full year. And the full year guide is 13-14% top-line growth, roughly $6 billion in incremental revenue.

JORDAN: And the context he gave was pretty staggering. They're calling themselves "still just getting started" — under 45% penetrated into their addressable 800 million households, and only capturing about 7% of a $670 billion addressable revenue market. That's a big runway claim.

ALEX: It is. Let's talk engagement, because this was clearly the hot topic on the call — multiple analysts pushed on viewing hours softening. Co-CEO Greg Peters gave this whole framework: quality, variety, quantity, and made the point that not all hours are created equal.

JORDAN: The live programming example was the standout for me. Live is about 5% of their content budget but only 1% of view hours — yet six of the top ten sign-up days in the last five years came from live events. Compare that to animation and kids' content, same 5% of spend, but 8% of view hours. Totally different jobs for the content to do.

ALEX: And the actual number — view hours grew 2% in the first half of 2026, a slight acceleration from 1.5% last year. So the "engagement is dying" narrative doesn't really hold up in the data they're showing.

JORDAN: Ted Sarandos also pushed back hard on the Season 2 drop-off question — said their second-season fall-off is actually slightly improved year over year, no change in release strategy needed.

ALEX: Let's get into content spend, because that's where the checkbook talk gets interesting. Content expense is up about 10% this year — higher than their five-year average of 8%, but still below the 14% decade average. So spend is accelerating a bit, but they're framing it as disciplined, growing slower than revenue.

JORDAN: And the slate highlights were fun — "I Will Find You" was their biggest original series launch this year, "Swapped" is tracking to be their second-biggest animated film ever behind K-Pop: Demon Hunters. Plus some great international examples — a Zimbabwean novel adapted into a South African hit called "The Polygamist," and "Rosario Tijeras" in Latin America getting a Season 6 greenlight.

ALEX: That global content engine is really Netflix's moat at this point. Now, let's talk monetization — ads and pricing. Greg Peters said they manage the ads business for total revenue growth, and there's still a gap between ad-tier ARM and the standard-without-ads tier ARM. He's framing that gap as "under-realized revenue" — basically future growth already baked into the roadmap as they close it.

JORDAN: On pricing, first-half price increases in the U.S., Mexico, and Spain are going "consistent with expectations" — no surprises there. And Peters made a value argument too — saying Netflix subscribers pay the least per hour of viewing compared to other SVOD services, with the ad tier at $8.99 in the U.S. being what he called an incredible entry point.

ALEX: Let's touch on some of the newer bets — gaming and AI. Cloud gaming had a strong quarter: FIFA and Unhinged were their two most successful cloud game debuts, and monthly active players for cloud games are up 11x since O

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**BETA FINCH — UnitedHealth Group (UNH) Q2 2026 Earnings Breakdown**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into UnitedHealth Group's second quarter 2026 results — a quarter that, honestly, marks a pretty big turnaround story.

JORDAN: Big turnaround is right. But before we get into it — quick reminder for everyone listening.

ALEX: Right, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good, now let's get into it.

ALEX: So let's start with the headline numbers, because they're strong. Adjusted EPS came in at $6.38, up from $4.08 a year ago — that's a huge jump. Revenue was about $112 billion, roughly flat year-over-year, but operating earnings grew 55%. And they raised full-year guidance to a range of $19.50 to $20 a share.

JORDAN: What jumps out to me is the medical care ratio — that's basically the percentage of premium revenue that goes out the door in medical claims. It dropped to 86.7% from 89.4% last year. Lower is better for the insurer. Part of that is $860 million in favorable prior-period development, meaning they overestimated costs in prior periods and get to release some of that reserve now. But even stripping that out, the underlying trend is improving.

ALEX: And this is really the story CEO Stephen Hemsley told at the top of the call — this is a company about a year into a restructuring after a rough stretch, and he was pretty clear: "we will remain restless." He's not declaring victory, but the discipline is showing up in the numbers.

JORDAN: Let's talk segments, because the picture is genuinely split. Medicare Advantage was the star of the quarter. Membership retention beat expectations, they now expect MA enrollment to decline by only about 1.1 million instead of more, and Medicare margins are tracking above 3% for the year. Medical trend also came in below their original 10% estimate — helped by benefit redesign, network curation, and honestly, a milder flu season.

ALEX: Meanwhile, commercial is the soft spot. Cost trends are running modestly above 11%, worse than they'd hoped. Management pointed to two specific culprits: the No Surprises Act's arbitration process — which they say is being exploited, with average payouts to out-of-network providers now 11 times what Medicare would pay — and more aggressive provider billing and coding practices.

JORDAN: That arbitration point was one of the more eye-opening moments in the Q&A. Executive Dan Kueter said roughly 60% of all arbitration cases are now brought by just five entities, and 40% of claims entering the process are actually ineligible to begin with. It's clogging the system and driving costs up. The upshot: commercial margin recovery, which they'd hoped to complete by 2027, is now going to take longer. Not derailed, in their words — just delayed.

ALEX: Medicaid, meanwhile, is basically playing out as planned — margins pressured, expected to land between -1% and -1.7% for the year, as state reimbursement rates lag behind medical cost growth. Nothing new there, just a slow grind toward better alignment with states.

JORDAN: Now let's flip to Optum, the services side of the business, because that's where a lot of the AI story lives. Optum Health — their value-based care arm — is showing real improvement: a roughly 10% reduction in hospitalizations in regions where they've rolled out new care transition programs, and patient satisfaction up about 5% year-over-year.

ALEX: Optum Rx, the pharmacy benefit manager, is leaning hard into transparency — they're on track to have more than 95% of clients on 100% rebate pass-through by year-end.

This episode includes AI-generated content.